- Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
More ▼
Key statistics
On Friday, Ultragenyx Pharmaceutical Inc (RARE:NSQ) closed at 41.40, 31.35% above the 52 week low of 31.52 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 41.24 |
---|---|
High | 41.76 |
Low | 40.98 |
Bid | 39.00 |
Offer | 43.75 |
Previous close | 41.77 |
Average volume | 741.01k |
---|---|
Shares outstanding | 83.13m |
Free float | 79.49m |
P/E (TTM) | -- |
Market cap | 3.45bn USD |
EPS (TTM) | -8.02 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼